Highly active antiretroviral therapy potently suppresses HIV infection in humanized Rag2-/-γc-/- mice

AIDS Research and Human Retroviruses

Volumn 26, Issue 7, 2010, Pages 735-746

  Sango, Kaori ^a   Joseph, Aviva ^a   Patel, Mahesh ^a   Osiecki, Kristin ^a   Dutta, Monica ^a   Goldstein, Harris ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; GLYCOPROTEIN GP 120; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; RAG2 PROTEIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DNA BINDING PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; INTERLEUKIN 2 RECEPTOR; RAG2 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POPULATION; CONTROLLED STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; INOCULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BLOOD; DEFICIENCY; DISEASE MODEL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; KNOCKOUT MOUSE; NEWBORN; PROCEDURES;

ANIMALS; ANIMALS, NEWBORN; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MICE; MICE, KNOCKOUT; RECEPTORS, INTERLEUKIN-2;

EID: 77954892271     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0136     Document Type: Article

References (50)

1. Van Rompay KK: Antiretroviral drug studies in nonhuman primates: A valid animal model for innovative drug efficacy and pathogenesis experiments. AIDS Rev 2005;7(2):67-83.
2. Giri M, Ugen KE, and Weiner DB: DNA vaccines against human immunodeficiency virus type 1 in the past decade. Clin Microbiol Rev 2004;17(2):370-389.
3. Letvin NL, Barouch DH, and Montefiori DC: Prospects for vaccine protection against HIV-1 infection and AIDS. Annu Rev Immunol 2002;20(1):73-99.
4. McCune JM: AIDS research: Animal models of HIV-1 disease. Science 1997;278(5346):2141-2142.
5. Aldrovandi GM, Feuer G, Gao L, et al.: The SCID-hu mouse as a model for HIV-1 infection. Nature 1993;363(6431):732-736.
6. Mosier DE, Gulizia RJ, Baird SM, Wilson DB, Spector DH, and Spector SA: Human immunodeficiency virus infection of human-PBL-SCID mice. Science 1991;251(4995):791-794.
7. Namikawa R, Weilbaecher KN, Kaneshima H, Yee EJ, and McCune JM: Long-term human hematopoiesis in the SCID-hu mouse. J Exp Med 1990;172(4):1055-1063.
8. Mosier DE, Gulizia RJ, Baird SM, and Wilson DB: Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 1988;335(6187):256.
9. Garcia S, Dadaglio G, and Gougeon ML: Limits of the human-PBL-SCID mice model: Severe restriction of the V beta T-cell repertoire of engrafted human T cells. Blood 1997; 89(1):329-336.
10. Markham RB and Donnenberg AD: Effect of donor and recipient immunization protocols on primary and secondary human antibody responses in SCID mice reconstituted with human peripheral blood mononuclear cells. Infect Immun 1992;60(6):2305-2308.
11. Roncarolo MG, Carballido JM, Rouleau M, Namikawa R, and de Vries JE: Human T-and B-cell functions in SCID-hu mice. Semin Immunol 1996;8(4):207-213.
12. Saxon A, Macy E, Denis K, Tary-Lehmann M, Witte O, and Braun J: Limited B cell repertoire in severe combined immunodeficient mice engrafted with peripheral blood mononuclear cells derived from immunodeficient or normal humans. J Clin Invest 1991;87(2):658-665.
13. Somasundaram R, Jacob L, Adachi K, et al.: Limitations of the severe combined immunodeficiency (SCID) mouse model for study of human B-cell responses. Scand J Immunol 1995;41(4):384-390.
14. DiSanto JP, Muller W, Guy-Grand D, Fischer A, and Ra-jewsky K: Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain. Proc Natl Acad Sci USA 1995;92(2):377-381.
15. Shinkai Y, Rathbun G, Lam KP, et al.: RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 1992;68(5):855-867.
16. Gimeno R, Weijer K, Voordouw A, et al.: Monitoring the effect of gene silencing by RNA interference in human CD34\+ cells injected into newborn RAG2-/-gammac-/-mice: Functional inactivation of p53 in developing T cells. Blood 2004;104(13):3886-3893.
17. Traggiai E, Chicha L, Mazzucchelli L, et al.: Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 2004;304(5667):104-107.
18. Legrand N, Weijer K, and Spits H: Experimental models to study development and function of the human immune system in vivo. J Immunol 2006;176(4):2053-2058.
19. An DS, Poon B, Ho Tsong Fang R, et al.: Use of a novel chimeric mouse model with a functionally active human immune system to study human immunodeficiency virus type 1 infection. Clin Vaccine Immunol 2007;14(4):391-396.
20. Baenziger S, Tussiwand R, Schlaepfer E, et al.: Disseminated and sustained HIV infection in CD34\+ cord blood cell-transplanted Rag2-/-gamma c-/-mice. Proc Natl Acad Sci USA 2006;103(43):15951-15956.
21. Berges BK, Akkina SR, Folkvord JM, Connick E, and Akkina R: Mucosal transmission of R5 and X4 tropic HIV-1 via vaginal and rectal routes in humanized Rag2-/-gammac-/-(RAG-hu) mice. Virology 2008;373(2):342-351.
22. Berges BK, Wheat WH, Palmer BE, Connick E, and Akkina R: HIV-1 infection and CD4 T cell depletion in the humanized Rag2-/-gamma c-/-(RAG-hu) mouse model. Retro-virology 2006;3:76.
23. Gorantla S, Sneller H, Walters L, et al.: Human immunodeficiency virus type 1 pathobiology studied in humanized BALB/c-Rag2-/-gammac-/-mice. J Virol 2007;81(6):2700-2712.
24. Zhang L, Kovalev GI, and Su L: HIV-1 infection and path-ogenesis in a novel humanized mouse model. Blood 2007; 109(7):2978-2981.
25. Joseph A, Zheng JH, Follenzi A, et al.: Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory activity. J Virol 2008;82(6):3078-3089.
26. Garcia F, Lejeune M, Climent N, et al.: Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J Infect Dis 2005;191(10):1680-1685.
27. Morikawa Y, Overton HA, Moore JP, et al.: Expression of HIV-1 gp120 and human soluble CD4 by recombinant ba-culoviruses and their interaction in vitro. AIDS Res Hum Retroviruses 1990;6(6):765-773.
28. Wang YH, Davies AH, and Jones IM. Expression and purification of glutathione S-transferase-tagged HIV-1 gp120: No evidence of an interaction with CD26. Virology 1995; 208(1):142-146.
29. Cook JE, Dasgupta S, Middaugh LD, et al.: Highly active antiretroviral therapy and human immunodeficiency virus encephalitis. Ann Neurol 2005;57(6):795-803.
30. Collins ML, Irvine B, Tyner D, et al.: A branched DNA signal amplification assay for quantification of nucleic acid targets below 100 molecules/ml. Nucl Acids Res 1997;25(15):2979-2984.
31. Katsoulidou A, Petrodaskalaki M, Sypsa V, et al.: Evaluation of the clinical sensitivity for the quantification of human immunodeficiency virus type 1 RNA in plasma: Comparison of the new COBAS TaqMan HIV-1 with three current HIV-RNA assays\LCx HIV RNA quantitative, VERSANT HIV-1 RNA 3.0 (bDNA) and COBAS AMPLICOR HIV-1 Monitor v1.5. J Virol Methods 2006;131(2):168-174.
32. Nicholson JK, McDougal JS, Jaffe HW, et al.: Exposure to human T-lymphotropic virus type III/lymphadenopathy-associated virus and immunologic abnormalities in asymptomatic homosexual men. Ann Intern Med 1985;103(1):37-42.
33. Fahey JL, Giorgi J, Martinez-Maza O, Detels R, Mitsuyasu R, and Taylor J: Immune pathogenesis of AIDS and related syndromes. Ann Inst Pasteur Immunol 1987;138(2):245-252.
34. Detels R, English PA, Giorgi JV, et al.: Patterns of CD4\+ cell changes after HIV-1 infection indicate the existence of a co-determinant of AIDS. J Acquir Immune Defic Syndr 1988; 1(4):390-395.
35. Garcia JV and Miller AD: Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nature 1991; 350(6318):508-511.
36. Sousa AE, Carneiro J, Meier-Schellersheim M, Grossman Z, and Victorino RM: CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol 2002; 169(6):3400-3406.
37. Dyrhol-Riise AM, Voltersvik P, Olofsson J, and Asjo B: Activation of CD8 T cells normalizes and correlates with the level of infectious provirus in tonsils during highly active antiretroviral therapy in early HIV-1 infection. AIDS 1999; 13(17):2365-2376.
38. Boasso A, Hardy AW, Anderson SA, Dolan MJ, and Shearer GM: HIV-induced type I interferon and tryptophan catabo-lism drive T cell dysfunction despite phenotypic activation. PLoS One 2008;3(8):e2961.
39. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with in-dinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337(11):734-739.
40. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997;337(11): 725-733.
41. Macchiarini F, Manz MG, Palucka AK, and Shultz LD: Humanized mice: Are we there yet? J Exp Med 2005;202(10): 1307-1311.
42. Klavinskis LS, Bergmeier LA, Gao L, et al.: Mucosal or targeted lymph node immunization of macaques with a par-ticulate SIVp27 protein elicits virus-specific CTL in the genito-rectal mucosa and draining lymph nodes. J Immunol 1996;157(6):2521-2527.
43. Lehner T, Bergmeier LA, Tao L, et al.: Targeted lymph node immunization with simian immunodeficiency virus p27 antigen to elicit genital, rectal, and urinary immune responses in nonhuman primates. J Immunol 1994;153(4): 1858-1868.
44. Browning J, Horner JW, Pettoello-Mantovani M, et al.: Mice transgenic for human CD4 and CCR5 are susceptible to HIV infection. Proc Natl Acad Sci USA 1997;94(26):14637-14641.
45. Wang EJ, Pettoello-Mantovani M, Anderson CM, Osiecki K, Moskowitz D, and Goldstein H: Development of a novel transgenic mouse/SCID-hu mouse system to characterize the in vivo behavior of reservoirs of human immunodeficiency virus type 1-infected cells. J Infect Dis 2002;186(10): 1412-1421.
46. Joseph A, Sango K, and Goldstein H: Novel mouse models for understanding HIV-1 pathogenesis. Methods Mol Biol 2009;485:311-327.
47. Yoshida A, Tanaka R, Murakami T, et al.: Induction of protective immune responses against R5 human immunodeficiency virus type 1 (HIV-1) infection in hu-PBL-SCID mice by intrasplenic immunization with HIV-1-pulsed dendritic cells: Possible involvement of a novel factor of human CD4(\+) T-cell origin. J Virol 2003;77(16):8719-8728.
48. Steyaert S, Verhoye L, Beirnaert E, et al.: The intraspleen huPBL NOD/SCID model to study the human HIV-specific antibody response selected in the course of natural infection. J Immunol Methods 2007;320(1-2):49-57.
49. Watanabe S, Terashima K, Ohta S, et al.: Hematopoietic stem cell-engrafted NOD/SCID/IL2Rgamma null mice develop human lymphoid systems and induce long-lasting HIV-1 infection with specific humoral immune responses. Blood 2007;109(1):212-218.
50. Choudhary SK, Rezk NL, Ince WL, et al.: Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4\+ T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2-/-{gamma}c-/-mouse. J Virol 2009;83(16):8254-8258.